December 3, 2004 |
Isis Pharmaceuticals Inc. said its experimental drug alicaforsen failed as a treatment for Crohn's disease in two late-stage trials. The Carlsbad, Calif.-based biotechnology company said it would focus on getting alicaforsen approved as an enema for patients with ulcerative colitis, a use shown to be effective in phase-two studies. Isis shares rose $1.09 to $6.01 on Nasdaq.
August 28, 1998 |
Isis Pharmaceuticals Inc. of Carlsbad has won approval to sell the first of a new kind of drug that treats disease by switching off genes. The drug, Vitravene, slows down a serious eye infection that can blind people with AIDS. The approval by the Food and Drug Administration cheered researchers who have spent three decades trying to prove that such treatments were possible.
September 17, 2002 |
Isis Pharmaceuticals Inc. said it and rival Sequitur Inc. have settled three patent infringement lawsuits involving biotechnology research. Terms weren't disclosed. Isis said it granted licenses for certain patents to Sequitur, which agreed to make payments to Isis and limit the types of chemistry, called antisense, it can use in research. Isis had claimed that Sequitur was using Isis technology without permission.
January 11, 2005 |
Isis Pharmaceuticals Inc. said Monday it planned to eliminate about 40% of its jobs to pare expenses and focus on developing a few key drugs, including an ulcerative colitis treatment. Writing down the value of assets such as equipment and patents will cost the company as much as $40 million in the fourth quarter. Additional expenses related to the firings will be recorded in the first quarter, Carlsbad, Calif.-based Isis said, without giving a specific figure.
January 6, 2004 |
Isis Pharmaceuticals Inc., which is developing drugs for cancer and autoimmune diseases, said Monday that an experimental medicine eased patients' rheumatoid arthritis symptoms in a study. The Carlsbad, Calif., company said 41% of patients who received the treatment had a measurable improvement. Rheumatoid arthritis is a crippling form of the joint disease, which primarily afflicts women. If approved, the medicine, known as Isis 104838, would compete against Amgen Inc.'
March 18, 2003 |
In a stunning setback, Isis Pharmaceuticals Inc. of Carlsbad, Calif., said its leading drug candidate -- a novel therapy for lung cancer -- failed in a closely watched test of 616 patients. Company executives said they were surprised by the results because earlier human tests seemed to show that the experimental biotech medication, Affinitak, would prolong patients' lives. Lung cancer affects more than 1 million people worldwide.